Cyclophilin A enhances macrophage differentiation and lipid uptake in high glucose conditions: a cellular mechanism for accelerated macro vascular disease in diabetes mellitus by Surya Ramachandran et al.
Ramachandran et al. Cardiovasc Diabetol  (2016) 15:152 
DOI 10.1186/s12933-016-0467-5
ORIGINAL INVESTIGATION
Cyclophilin A enhances macrophage 
differentiation and lipid uptake in high glucose 
conditions: a cellular mechanism for accelerated 
macro vascular disease in diabetes mellitus
Surya Ramachandran* , Anandan Vinitha and Cheranellore  Chandrasekharan Kartha*
Abstract 
Background: Vascular disease in diabetes is initiated by monocyte adhesion to vascular endothelium, transmigra-
tion and formation of foam cells. Increasing clinical evidence supports a role for the secretory protein, cyclophilin A in 
diabetic vascular disease. The means by which cyclophilin A contributes to vascular lesion development in diabetes is 
however largely unknown.
Methods: In this study we investigated using THP1 cells and human monocytes whether cyclophilin A under hyper-
glycemic conditions, functions in the inflammatory cascade as a chemoattractant and increases lipid uptake by for-
mation of foam cells invitro. We developed an invitro model of monocytes cultured in 20 mm glucose (high glucose) 
equivalent to 360 mg/dL of plasma glucose levels. These monocytes were then differentiated into macrophages using 
PMA and subsequently transformed to lipid laden foam cells using oxidized low density lipoproteins in the presence 
and absence of cyclophilin A. This cellular model was used to study monocyte to macrophage differentiation, transmi-
gration and foam cell formation. A similar cellular model using siRNA mediated transient elimination of the cyclophilin 
A gene as well as chemical inhibitors were used to further confirm the role of cyclophilin A in the differentiation and 
foam cell formation process.
Results: Cyclophilin A effectively increased migration of high glucose treated monocytes to the endothelial cell 
monolayer (p < 0.0001). In the presence of cyclophilin A, differentiated macrophages, when treated with oxLDL had 
a 36 percent increase in intracellular lipid accumulation (p = 0.01) when compared to cells treated with oxLDL alone. 
An increased flux of reactive oxygen species was also observed (p = 0.01). Inflammatory cytokines such as TNF-α, 
MCP-1 and cyclophilin A were significantly increased. Silencing cyclophilin A in THP-1 cells and human monocytes 
using siRNA or chemical inhibitor, TMN355 resulted in decrease in lipid uptake by 65–75% even after exposure to 
oxidized LDL. The expression of scavenger receptors expressed during differentiation process, CD36 and LOX-1 were 
decreased (p < 0.0001). Levels of extracellular cyclophilin A and other inflammatory cytokines such as TNF-α and MCP-
1also significantly reduced.
Conclusions: Taken together, we describe here a possible cellular basis by which cyclophilin A may accelerate 
atherogenesis in diabetes mellitus.
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Background
The risk of vascular complications in patients with dia-
betes mellitus is altered by chronic hyperglycemia, 
increased reactive oxygen species and abnormal activa-
tion of several molecules. Chronic inflammatory pro-
cesses in the vascular wall begins with recruitment of 
monocytes, increased monocyte transmigration, vascu-
lar permeability, differentiation into tissue macrophages 
eventually leading to formation of lipid laden foam cells. 
Monocytes function as sentinel cells during atherogen-
esis. Monocytes adhere to endothelial cells and later 
migrate into the subendothelial space in response to 
chemotactic activation. These monocytes differentiate 
into macrophages and take up oxidized lipids. The cells 
transform into cholesterol laden foam cells. These foam 
cells can become apoptotic and together with cellular 
debris contribute to fatty lesions leading to atheroscle-
rotic plaque formation. High blood glucose levels further 
facilitate monocyte adhesion to endothelial cells, dif-
ferentiation of monocyte into macrophages ultimately 
promoting atherogenesis [1], thus increasing the risk 
of vascular disease in diabetes mellitus. The regulatory 
signals for monocyte transmigration, differentiation 
and foam cell formation in the vascular wall in a dia-
betic milieu are not completely understood. In an earlier 
study we found that high glucose activates monocytes to 
secrete proteins which may increase the risk for vascular 
lesion formation [2]. One such protein is cyclophilin A, 
an immunophilin which has also been discovered to be 
elevated in the blood of patients with type 2 diabetes as 
well as patients with coronary artery disease [3, 4].
Cyclophilin A is present in monocytes [3], endothe-
lial cells [5] and vascular smooth muscle cells [6]. It is 
also secreted from these cells in response to inflamma-
tory stimuli such as hyperglycemia, hypoxia, infection 
and oxidative stress [5, 6]. Plasma levels of extracel-
lular cyclophilin A correlates with anatomical severity 
of stable coronary artery disease [7]. Serum cyclophilin 
A concentration is significantly higher in subjects with 
unstable angina and acute myocardial infarction than in 
patients with stable angina and controls [8]. Cyclophi-
lin A increases endothelial cell activation and inflam-
mation in vascular wall cells [9]. Secreted cyclophilin A 
activates endothelial cells, which in turn contributes to 
recruitment of circulatory monocytes [10]. Overall, there 
is evidence that cyclophilin A can be implicated in the 
pathogenesis of vascular inflammation.
The purpose of this study was to establish in an invitro 
cellular model, the ability of cyclophilin A to induce 
monocyte adhesion to endothelial cells, migration of 
monocytes as well as formation of foam cells, to explore 
cellular mechanisms for accelerated atherosclerosis in 
diabetes mellitus. Our findings indicate a pivotal role 
for cyclophilin A in increasing monocyte migration and 




Phorbol 12-myristate 13-acetate (P-8139), LPS (L-5293), 
oil red O stain (O-1391), Hoechst 33258 (#861405), mis-
sion siRNA (EHU-107101), Histopaque (1077), Trichloro 
Acetic Acid (TCA) (T6399), 2 Thiobarbituric Acid (T5500), 
Malondialdehyde tetrabutylammonium salt (36357), Buty-
lated hydroxytoluene (W218405) were procured from 
Sigma Aldrich, USA. Cyclophilin A recombinant pro-
tein (3589-CA) and TMN 355 (#4152) were purchased 
from R & D systems Inc., USA. Dil labeled oxidized LDL 
(J-64164) and dil labeled acetylated LDL (J-65597) were 
obtained from Alfa Aesar, USA. Mouse anti-cyclophilin 
A (ab-58144), anti mouse IgG HRP (ab-6789), Anti-LOX 
1 antibody (ab60178), anti rabbit IgG-HRP (ab-97051) and 
catalase assay kit (ab83464) were purchased from Abcam, 
UK. Mouse anti β Actin (sc-47778) and rabbit anti-CD 36 
(#14347) was purchased from Cell Signaling Technology, 
USA and Santa Cruz, USA respectively. Protease inhibi-
tor cocktail tablets (#04 693 159001) was purchased from 
Roche, Switzerland. CD 14 MicroBeads (human) (130-
050-201), CD 14—FITC, Human (clone: TUK4) (130-098-
063) were purchased from Miltenyi Biotech, Germany. 
CellROX Deep Red Reagent (c10422) was purchased from 
Thermo Fisher Scientific, USA. All other reagents used for 
assays were of analytical grade.
Culturing and treatment of THP cell lines and human 
monocytes
Monocyte cell lines, THP1 were obtained from American 
Type Culture Collection (ATCC No: THP1 (ATCC® TIB-
202™) USA. Cells were cultured in 10% RPMI 1640 
medium (Gibco, USA). We developed an invitro model 
of monocytes cultured in 20  mM glucose equivalent 
to 360  mg/dL of plasma glucose levels in human sub-
jects. Cells treated with mannitol (9.5 mM) was used as 
hyperosmolar control as described previously [2]. THP-1 
cells were differentiated into macrophages by treating 
with 50 ng/mL PMA for 96 h. EA.hy926  (ATCC® CRL-
2922) cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (Gibco, USA).
Primary monocytes were isolated from blood of healthy 
human volunteers as described earlier [2]. This study was 
approved by the Human Ethics Committee of Rajiv Gandhi 
Centre for Biotechnology (IHEC No: IHEC/01/2014/06). 
All study subjects signed the written informed consent. All 
methods were performed in accordance with the human 
ethics guidelines. All subjects had a normal fasting glu-
cose level of 70–110  mg/dL. Their lipid levels were also 
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in the normal range (<200). None of the subjects were on 
medication nor had any known disease. Briefly, peripheral 
blood mono nuclear cells (PBMCs) were isolated using 
Histopaque (Gibco) and incubated with anti CD14 mAb 
coated microbeads (Miltenyi Biotech). The CD14+  cells 
which were magnetically retained on the beads were eluted 
and checked for efficiency using flow cytometry (data not 
shown). Each experiment was done in triplicates as three 
independent experiments.
In vitro monocyte transmigration model
We created an invitro cellular model of monocyte migra-
tion, chemotaxis and transmigration using THP cells 
and immortalized endothelial cell line EA.hy926  as 
monolayers.
Monocyte migration assay
Cell migration was evaluated using Transwell inserts 
(6.5  mm diameter) (Corning Costar) in 24 well plates. 
Pre-treated THP cells (50,000 cells/well) were added 
to the upper chamber of the insert. The lower chamber 
contained 1 mL of normal glucose (NG) or high glucose 
(HG) (20 mM) RPMI/1% human albumin with or without 
cyclophilin A as chemokine. LPS (10 µg/mL) was used as 
positive control throughout the experiments. The plates 
were incubated for 4–24  h and stained with Giemsa’s 
stain (Merck Chemicals). The number of cells appear-
ing on the lower face of the filter was recorded in three 
random fields for each well. The chemotactic index (CI) 
was calculated as the number of cells migrating towards 
the test sample divided by the number of cells migrat-
ing towards the control medium using light microscopy. 
The number of cells migrating to the bottom chamber 
was counted by flow cytometry. The inserts were fixed 
with 4% para-formaldehyde (PFA) and stained with 
giemsa’s stain. The cells migrating to the reverse surface 
of the membrane were counted by light microscopy at 
20× magnification in four different random fields. After 
migration the cells in lower chamber were counted and 
analyzed directly by flow cytometry (Becton–Dickinson).
Transendothelial migration
EA.hy926 (4 × 105) cells were cultured on 24 mm diam-
eter polycarbonate membrane (8.0 micron pore size), 
(Corning Costar). The LPS activated THP-1 cells were 
seeded in the upper chamber. Cyclophilin A (100 ng/mL) 
was added in the lower chamber [11]. After incubation, 
the cells were collected from the lower chamber and ana-
lysed by flow cytometry.
Monocyte to macrophage differentiation
Monocyte to macrophage differentiation was induced 
with PMA at a final concentration of 50 μg/mL in THP 1 
cells cultured in both normal glucose and high glucose in 
the presence and absence of cyclophilin A for 96 h. Dif-
ferentiated cells were observed in white field using trans-
mitted detector (TD) of a confocal microscope (Leica 
SP2 Laser scanning Spectral Confocal system).
Lipid accumulation by macrophages
THP1 cells (1 × 105) were seeded on rounded cover slips 
and treated with PMA (50  ng/mL) in 10% high glucose 
(20  mM glucose) RPMI 1640 medium with or without 
cyclophilin A. After differentiation, the cells were starved 
for 24  h  and incubated with OxLDL (50  µg/mL) for 
24  h [12]. Lipid uptake by macrophages was quantified 
by oil red O staining, immunocytochemistry and flow 
cytometry.
Oil red O (ORO) staining
Cells were fixed with 4% paraformaldehyde (PFA) and 
stained with oil red O (ORO; Sigma). ORO staining was 
analyzed by light microscopy (Nikon ECLIPSE Ti-U, 
USA) and quantified using Nikon’s comprehensive imag-
ing software NIS Elements. LDL uptake was expressed as 
the number of ORO-positive cells per 10 × field (average 
of 3 different areas, n = 3 experiments per group) [12].
Immunofluoresence assay
Uptake of DiI-oxLDL was studied either with confocal 
microscopy or fluorescence-activated cell sorting (FACS). 
Differentiated THP cells were treated with DiI-oxLDL 
in presence and absence of cyclophilin A for 4  h. Cells 
were treated with 10  µg/mL of Hoechst 33258 (Sigma) 
for 5 min. The cells were then placed for confocal micros-
copy and quantified using microscope imaging software 
NIS-Elements Viewer.
Flow cytometry analysis
THP1 differentiated macrophages were incubated with 
DiI-oxLDL (10  µg/mL) for 24  h with or without cyclo-
philin A. The specificity of uptake was tested by pretreat-
ing the cells with 50-fold excess of unlabeled oxLDL for 
30  min and then incubation with dil labeled oxidized 
LDL for 4  h as described earlier [12]. The intensity was 
analyzed by fluorescence-activated cell sorting (FACS) 
(Becton–Dickinson) using FACS Diva v8.0 software. 
Cells were quantitated by subtracting the cell autofluo-
rescence of the treated samples and expressed as mean 
fluorescence intensity.
Immunoblotting analysis
After treatment with OxLDL and cyclophilin A, pro-
tein lysates were prepared and separated on SDS-PAGE 
and resolved proteins were transferred on to nitrocel-
lulose membrane. The membrane was incubated with 
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1:1000 dilutions of each of the following primary anti-
bodies at 4  °C for 18  h: Mouse anti-cyclophilin A (ab-
58144), Mouse anti β Actin (sc-47778), rabbit anti-CD 
36 (#14347), Rabbit anti-LOX-1 (ab174316) as per man-
ufacturer’s instructions. The membrane was then incu-
bated with specific secondary antibodies: anti mouse 
IgG HRP (ab-6789) and anti rabbit IgG-HRP (ab-97051) 
at a dilution of 1:5000. The proteins were visualized with 
clarity western ECL substrate. The bands were analyzed 
by Quantity One 1D image analysis software (Bio-Rad, 
USA).
Enzyme linked assay for measurement of cyclophilin A, 
TNF‑α and MCP‑1 levels in conditioned medium
Levels of the cytokines TNF-α and MCP-1 as well as 
cyclophilin A in conditioned medium after treatment 
was determined with a sandwich immunoassay kit (R&D 
systems, Uscn Life Science Inc) as per manufacturer’s 
instructions. The linearity of the kit was assayed by test-
ing samples spiked with a known concentration of pro-
teins and their serial dilutions. All samples were analyzed 
in duplicate. To maintain assay precision, samples with a 
CV >12% were excluded.
Invitro silencing of cyclophilin A gene
THP1 cells (2–4  ×  105) were transfected with mission 
siRNA (7 pmol) using, mission siRNA Transfection Rea-
gent (Sigma Aldrich) for 48  h and TMN 355 for 6  h at 
37  °C. Primers used for cyclophilin A mRNA target 
sequence were 5′-TGGTGTTTGGCAAAGTGAAAGAA 
GGCATGAATATTGTGGAGGCCATGGAGCGCT 
TTG -3′. The efficiency of silencing was measured by 
quantitative real time PCR by measuring relative mRNA 
expression using ABI Prism 7900HT sequence detec-
tion system. Total RNA was isolated from the cells using 
TRIzol reagent (Sigma), according to the manufacturer’s 
instructions. RNA yield and purity were calculated by 
spectrophotometric analysis. Total RNA (10  μg) from 
each sample was reverse transcribed using random hex-
amers, dNTPs, and M-MLV reverse transcriptase (Pro-
mega). PCR of cDNA was performed using specific 
primers of cyclophilin A. The reactions were performed 
in triplicate in 96-well plates at 48 °C, 30 min; 95 °C, 10 
min; then 95 °C, 15 s; and 60 °C, 1 min; for 40 cycles. A 
dissociation curve was constructed by increasing the 
temperature from 60 to 95 °C at a ramp rate of 2%. A sin-
gle peak was observed in the dissociation curve of cyclo-
philin A gene, supporting the specificity of the RT-PCR 
product. Ct values were used to calculate the expres-
sion levels of cyclophilin A gene normalized to endog-
enous cellular beta 2 microglobulin. The levels of beta 
2 microglobulin mRNA was measured in parallel using 
specific primers from Sigma. The primer sequences of 
cyclophilin A and beta 2 microglobulin are given in the 
Additional file 1.
Treatment of cyclophilin A with its chemical inhibitor, TMN 
355
THP 1 differentiated macrophages were treated with 
TMN 355 at a concentration of 1 µM/mL for 6 h. Time 
and concentration of TMN 355 treatment was standard-
ized by calculating LC 50 values using MTT assay [13].
Oxidative stress analysis
PMA differentiated macrophages were incubated with 
oxidised LDL (50 µg/mL) for 24 h.
ROS levels by cell ROX Deep Red Reagent using flow 
cytometry
ROS levels were measured using cell ROX Deep Red 
Reagent (Thermofisher scientific). THP1 cells were incu-
bated with oxLDL and cyclophilin A to induce oxidative 
stress. After incubation, cells were treated with cell rox 
reagent at a final concentration of 5 µM and analyzed by 
flow cytometry.
Lipid peroxidation by TBARS assay
Lipid peroxidation by TBARS assay was measured as 
described earlier [14]. Briefly, THP 1 cells were seeded 
on six-well plates in a medium containing cyclophilin A 
and oxidized lipoprotein to induce oxidative stress. After 
incubation, the cells were washed and resuspended in 
PBS containing 150  mM butylated hydroxytoluene. The 
cell suspension was mixed with a solution containing 
30% trichloroacetic acid, 0.75% thiobarbituric acid, and 
0.5  N hydrochloric acid. Samples were heated at 60  °C 
for 15  min before they were centrifuged for 8  min at 
13,600g. The absorbance of the supernatants was meas-
ured at 532 nm. TBARS was calculated as malondialde-
hyde equivalents present using an extinction coefficient 
of 1.56 × 105 M−1 cm−1.
Catalase assay
Catalase activity was measured by catalase assay kit 
(Abcam,UK) as per manufacturer’s instructions. Briefly, 
PMA differentiated macrophages were treated with 
OxLDL in the presence and absence of cyclophilin A 
(100  ng/mL) for 24  h. Cells were harvested after treat-
ment, washed with cold PBS twice and homogenized with 
200  µL of cold assay buffer. To start the reaction  12  µL 
of 1  mM H2O2 was added and incubated for 30  min at 
25  °C. The unconverted H2O2 was measured calorimet-
rically using OxiRed probe at 530  nm using microplate 
reader (Biorad laboratories, Germany). Catalase activity 
was calculated as the amount of H2O2 decomposed per 
minute at pH 4.5 at 25 °C.
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Statistical analysis
All assays were conducted as three separate experiments 
in triplicates. Results were recorded as percentage. The 
differences between various cell treatments were ana-
lyzed using one way linear analysis of variance (ANOVA) 
using GraphPad Prism, by GraphPad Software, Inc. 
p < 0.05 were considered statistically relevant.
Results
Cyclophilin A increases monocyte adhesion 
and transmigration into the endothelium under high 
glucose conditions
The inflammation cascade begins with adhesion of 
monocytes to the endothelial cells and transmigra-
tion into the intima. We speculated that cyclophilin A 
under hyperglycemic conditions functions as a che-
moattractant and influences the adhesion process. To 
understand whether cyclophilin A has the potential to 
increase monocyte adhesion we conducted chemotaxis 
and transmigration experiments. A dosage of 100 ng/mL 
cyclophilin A was used for all experiments [10]. Migra-
tion was assessed from 4 to 24 h by calculating chemo-
tactic index (Fig.  1a). At an optimum time of 12  h the 
filters were fixed and stained with Giemsa. The pictures 
of filter stained with Giemsa reveals increase in number 
of cells that have adhered to the filter on treatment with 
high glucose and cyclophilin A (Fig.  1b). Treatment of 
monocytes cells cultured in high glucose with 100 ng/mL 
cyclophilin A in the lower chamber markedly increased 
migration of monocytes compared to untreated cells 
(Fig. 1c). Transendothelial migration of activated mono-
cytes across monolayer of endothelial cells increased 
substantially with the addition of cyclophilin A in the 
lower chamber in high glucose conditions compared to 
untreated control group. The migrated cells across EaHy 
cells in normal glucose conditions were very few in num-
ber to be counted using flow cytometry. LPS, a known 
chemokine, was used as positive control (Fig. 1d).
Cyclophilin A affects monocyte to macrophage 
differentiation
To investigate the effect of cyclophilin A on the process 
of monocyte differentiation into macrophages, THP 
cells were cultured for 96 h in 10% RPMI 1640 contain-
ing phorbol myristate acetate (PMA) in the presence and 
absence of cyclophilin A in both normal and high glu-
cose conditions. THP-1 cells incubated in the presence 
of cyclophilin A were flattened and had developed cyto-
plasmic processes (Fig. 2A). The expression of scavenger 
receptor markers, cluster of differentiation 36 (CD36) 
and lectin-type oxidized LDL receptor 1 (LOX-1) were 
significantly increased on treatment of monocytes with 
cyclophilin A (Fig. 2B).
Cyclophilin A induces oxLDL uptake and stimulates 
monocyte derived macrophage foam cell formation 
in vitro
We investigated whether priming of macrophages with 
cyclophilin A promotes lipid uptake in THP-1 derived 
macrophages. Lipid endocytosis in macrophages was 
measured using DiI labeled oxidized low density lipopro-
tein (DiI OxLDL) treatment for 4 h. Cyclophilin A dose 
dependently increased the accumulation of lipid droplets 
in macrophages. From a dose of 50 ng/mL of cyclophilin 
A onwards, lipid uptake was significantly increased. Max-
imal effects were observed at a dose of 100  ng/mL. At 
higher doses no such significant difference was observed 
(Fig.  3a). This dosage was considered for all further 
experiments [10]. Cyclophilin A treated macrophages 
had increased uptake of DiI labeled OxLDL compared 
with untreated cells, as evident from oil red O (ORO) 
staining visualized by light microscopy (Fig. 3b), fluores-
cence microscopy (Fig. 3c) and flow cytometry (Fig. 3d). 
Cells have an inherent lipid content which stains red on 
treatment with DiI even in the absence of OxLDL. Expo-
sure to cyclophilin A in the presence of OxLDL markedly 
increased the uptake of lipids by cells.
(See figure on next page.) 
Fig. 1 a Chemotactic response was analyzed using transwell assays as described in the method section. THP-1 cells were treated with or without 
cyclophilin A (100 ng/mL) for 4, 6, 12, 24 h. LPS (10 µg/mL) was taken as positive control. b Monocytes were cultured on the upper chamber of 
transwells in normal glucose (NG) and high glucose (HG) in the presence and absence of cyclophilin A (lower chamber) for 24 h. The adhered mono-
cytes were stained using Giemsa stain. HG indicates RPMI 1640 culture media primed with high glucose (20 mM/L). (c) Flow cytometry analysis of 
cells after transmigration assays. Transwell experiments were performed using 5.0 micron pore membrane. To test the migration rate, THP 1 cells 
were seeded on top of the transwell and 100 ng/mL cyclophilin A was added to the bottom of chambers along with NG (left panel)/HG (right panel) 
media. Migration rate of THP cells cultured in HG treated with cyclophilin A were similar to cells treated with LPS alone indicating a strong chemoki-
netic activity by cyclophilin A. d Transendothelial migration of THP 1 cells across monolayer of endothelial cells (EaHy). THP-1 cells were seeded 
on top of the transwell and 100 ng/mL cyclophilin A was added to the bottom of the chamber. After 24 h of incubation transmigrated cells were 
counted by flow cytometry using Hoechst (10 µg/mL) as nuclear stain. Transendothelial migration of cyclophilin A treated cells were almost equal 
to that of positive control, LPS. Data are presented as mean ± SD (n = 3). Chemotactic response was analyzed using two-way ANOVA. p < 0.005 
was considered significant
Page 6 of 19Ramachandran et al. Cardiovasc Diabetol  (2016) 15:152 
Page 7 of 19Ramachandran et al. Cardiovasc Diabetol  (2016) 15:152 
Invitro silencing of Cyclophilin A gene reduces lipid uptake 
by high glucose primed macrophages
To study the effect of intracellular cyclophilin A in lipid 
uptake by monocytes and extracellular secretion of 
cyclophilin A, we attempted to silence the cyclophilin A 
gene in macrophages. We used mission small interfer-
ing RNA (siRNA) to knockdown cyclophilin A in mono-
cyte differentiated macrophages using MISSION siRNA 
Fig. 2 A THP cells were cultured for 96 h in 10% RPMI 1640 containing PMA in the presence of cyclophilin A (100 ng/mL) in NG/HG conditions to 
induce differentiation. The differentiation of monocyte to macrophage was analysed by transmitted detector of confocal microscopy. THP-1 cells 
incubated in the presence of cyclophilin A and HG exhibited cell flattening and development of cytoplasmic processes. B Western blot analysis 
of scavenger receptor markers, CD 36 and LOX 1 of glucose activated monocyte differentiated macrophages after treatment with cyclophilin A 
(100 ng/mL). Cyclophilin A treated macrophages in high glucose conditions resulted in a significant increase in LOX-1 and CD36 protein expression. 
Protein densities of immunoreactive bands measured by the Quantity One 1D analysis software program. Data are presented as mean ± SD (n = 3) 
and asterisk represents p < 0.05
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transfection reagent. There was 70–85% transfection effi-
ciency, as evident from quantitative analysis by real time 
PCR (Fig.  4a). The gene silencing effect of cyclophilin 
A mission siRNA was confirmed at the protein level by 
western blotting (Fig.  4b). Knockdown of cyclophilin A 
with siRNA resulted in significant reduction (p < 0.05) in 
lipid uptake by macrophages (Fig. 4c). We also confirmed 
that cyclophilin A could be suppressed by siRNA within 
48  h and decrease the expression of scavenger receptor 
markers, CD 36 and LOX 1 eventually reducing lipid 
uptake by macrophages (Fig.  4d). Expression of CD 36 
and LOX 1 remained increased in macrophages which 
were treated with cyclophilin A.
Parallely with reduction of cyclophilin A protein 
expression, the levels of other inflammatory cytokines 
such as monocyte chemoattractant protein-1 (MCP 1), 
tumor necrosis factor alpha (TNF α) as well as extracel-
lular cyclophilin A determined by enzyme-linked immu-
nosorbent assay (ELISA) were reduced in cyclophilin A 
silenced monocyte differentiated macrophages (Fig.  4e). 
This is in contrast to the increased levels of cytokines in 
non-silenced cells treated with OxLDL and cyclophilin A 
(Fig. 4e).
TMN355, a chemical inhibitor of cyclophilin A reduces 
foam cell formation and cytokine secretion
Here, we tested the effect of a chemical inhibitor of 
cyclophilin A on lipid uptake by monocyte derived 
macrophages. TMN 355 (2-Chloro-N-[(9H-fluoren-
9-ylamino)carbonyl]-6-fluorobenzamide) is a potent 
inhibitor of cyclophilin A which contains an amide 
linker that contributes to inhibitory activity via form-
ing 2–3 hydrogen bonds with residues Arg55, Gln63, 
and Asn102 around the “saddle” between the two 
sub-binding pockets of cyclophilin A and thus inhib-
iting the cis–trans isomerase activity of cyclophilin 
A [15]. It is 27 times more potent than cyclosporine 
A and is void of the immunosuppressive function of 
cyclosporine. Being a chemical compound, we initi-
ated this study with a cell viability assay using MTT 
(3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
Bromide) in a time and dose dependent manner. A dose 
of 1  μM TMN 355 was found to inhibit cyclophilin A 
expression without affecting cell viability (Fig. 5a). Hence, 
1  μM TMN 355 was used to inhibit cyclophilin A after 
6 h of activation.
Interestingly, the treatment with TMN 355 resulted 
in 75.9% reduction of cyclophilin A protein expression 
(Fig.  5b). This indicates that TMN 355 affects not only 
the enzyme activity but also protein level expression. To 
further understand the mechanism of action of TMN355 
on cyclophilin A protein expression, we measured tran-
script levels of cyclophilin A in TMN 355 treated mac-
rophages using real time quantitative PCR. The mRNA 
levels of cyclophilin A was decreased in TMN 355 treated 
macrophages (Fig.  5c) in agreement with the protein 
expression in Fig. 5b [16].
We next examined the biological effect of TMN 355 on 
lipid uptake by macrophages. A dose of 1 μM TMN 355 
caused a marked decrease in lipid uptake as evident from 
immunofluoresence assay (Fig.  5c). The ability of TMN 
355 to reduce foam cell formation was also determined 
by immunoblotting experiments (Fig. 4c). Similar to the 
observations in knockdown experiments using siRNA, 
the levels of proinflammatory cytokines TNF α, MCP1 
and extracellular cyclophilin A were significantly reduced 
in monocyte derived macrophages on inhibition using 
TMN 355 (Fig. 4d).
Cyclophilin A induces foam cell formation in human 
monocytes
The effect of cyclophilin A on monocyte differentiation 
into macrophages and foam cell formation was further 
studied on freshly isolated human monocytes cultured 
for 96  h in RPMI 1640 in the presence and absence of 
cyclophilin A. Monocytes were differentiated into mac-
rophages and then treated with OxLDL for 4 h. Cyclophi-
lin A treatment resulted in the increased expression of 
CD 36 and LOX1 in cells primed with OxLDL. There was 
a marked decrease in the expression of CD36 and LOX1 
(See figure on next page.) 
Fig. 3 a THP cells were treated with cyclophilin A at doses of 10, 25, 50, 100 and 150 ng/mL in the presence of high glucose (HG). HG indicates 
RPMI culture media primed with glucose (20 mM/L). Lipid uptake was measured using confocal microscopy after treatment with oxidized LDL for 
4 h. Maximal effect was observed at a dosage of 100 ng/mL of cyclophilin A. b Photomicrographs of lipid laden macrophages stained with oil red O 
(ORO). THP cells were treated with/without cyclophilin A (100 ng/mL) and oxidized LDL in both normal glucose (NG) and high glucose (HG) condi-
tions for 24 h before staining with ORO. Abundant ORO positivity was seen in cells treated with oxLDL and cyclophilin A cultured in HG conditions. 
c Confocal images of Dil-oxLDL uptake in THP cells differentiated to macrophages in the presence of cyclophilin A (100 ng/mL). Dil-oxLDL uptake 
is shown in red. Cells were counterstained with Dapi (blue). Inset is the enlarged image of a foam cell showing red coloured lipid droplets. Acety-
lated LDL (Ac LDL) was taken as the positive control. Mean intensity was quantified using microscope imaging software NIS-Elements Viewer. Cells 
treated with ox LDL had extensive lipid uptake compared to control cells. d Flow cytometric analysis of Dil-OxLDL uptake by macrophages before 
and after treatment with cyclophilin A in high glucose conditions. Cells were treated with and without cyclophilin (100 ng/mL) for 24 h and then 
labeled with DiI Ox-LDL for 4 h. The fluorescence intensity was analyzed by FACS using FACS Diva v8.0 software. Cells were quantitated by subtract-
ing the cell autofluorescence of the treated samples and expressed as mean fluorescence intensity
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when the macrophages were treated with siRNA or TMN 
355 (Fig. 6a). The uptake of DiI OxLDL, analyzed by con-
focal microscopy, was increased in cyclophilin A treated 
monocytes, which was effectively reduced by 65.3% on 
siRNA treatment and 77% by chemical inhibition using 
TMN 355 (Fig. 6b), (p < 0.005).
Cyclophilin A induces oxidative stress during foam cell 
formation in hyper glycemic conditions
We observed an increase in secretion of inflammatory 
cytokines such as MCP 1, TNF-α as well as cyclophilin 
A by monocyte differentiated macrophages primed with 
OxLDL. This led us to investigate whether cyclophi-
lin A activates cells to produce reactive oxygen species 
(ROS). The cell ROX Deep Red Reagent detects super-
oxide localized in the cytoplasm in living cells. To inves-
tigate the effect of cyclophilin A in lipid peroxidation, 
we treated the monocyte differentiated macrophages 
with cell ROX reagent at a final concentration of 5 µM. 
Lipid peroxidation was assayed by flow cytometry using 
fluorescent probes cell ROX. As illustrated in Fig.  7a, 
cyclophilin A substantially increased OxLDL induced 
cytosolic ROS production (p  <  0.0001). We also meas-
ured the level of malondialdehyde (MDA), another well 
studied marker of lipid peroxidation. MDA is reported 
to impair the interaction between oxidized lipopro-
tein and macrophages thereby promoting atherosclero-
sis [17]. It is quantified using a calorimetric assay based 
on the reaction between MDA and thiobarbituric acid 
(TBA). We used the TBARS assay to assess oxidative 
stress on treatment of macrophages with cyclophilin A. 
As illustrated in Fig.  7b, treatment with cyclophilin A 
significantly increased the amount of lipid peroxides in 
the macrophages (p < 0.0001). The production of ROS is 
regulated by antioxidant enzymes such as catalase [18]. 
Excessive ROS production which cannot be buffered by 
antioxidant enzyme results in oxidative stress. Catalase 
functions to catalyze the decomposition of hydrogen per-
oxide to water and oxygen. Catalase activity is reversibly 
proportional to the signal. Our experiment with catalase 
assay kit (abcam) indicate that oxidative stress increases 
on treatment of macrophage with oxidized lipoprotein 
and cyclophilin A (p < 0.0001) (Fig. 7c).
Discussion
In this report we provide evidences that cyclophilin A 
in high glucose conditions can function as a chemoat-
tractant increasing monocyte adhesion to the endothe-
lium and enhance transmigration and differentiation 
of monocytes to foam cells. We also demonstrate that 
cyclophilin A induces lipid uptake by macrophages and 
that inhibition of cyclophilin A can prevent foam cell 
formation through an oxidative stress induced pathway. 
Taken together, our results suggest that cyclophilin A is 
an important regulator of vascular inflammation in dia-
betes mellitus.
Hyperglycemia causes damage to the vascular wall 
through several mechanisms that include: increased 
flux of glucose through the polyol pathway; activation 
of protein kinase C (PKC) isoforms; overactivation of 
the hexosamine pathway; increased intracellular forma-
tion of advanced glycation end products (AGEs) and 
expression of its receptors and ligands [19]. Endothelial 
cells cultured in high glucose demonstrate abnormal cell 
cycles, slow replication and increase in apoptosis [20]. All 
these pathways lead to increased oxidative stress. ROS 
(See figure on previous page.) 
Fig. 4 a Transfection efficiency was analyzed using real time PCR after treatment of THP differentiated macrophages with mission siRNA (7 pmol) 
for 48 h. b Immunoblotting image of cyclophilin A protein expression after treatment with mission siRNA to confirm transfection. β-actin was used 
as endogenous control. Protein densities of immunoreactive bands measured by the Quantity One 1D analysis software program. Data are pre-
sented as mean ± SD (n = 3) and asterisk represents p < 0.05). c Confocal images of foam cell formation after transient transfection of cyclophilin 
A using mission siRNA for 48 h. The transfected cells were treated with DiI conjugated oxLDL. Dapi was used as the nuclear stain. Mean intensity 
was quantified using microscope imaging software NIS-Elements Viewer, *p < 0.05 was considered significant. d Western blot analysis of cyclo-
philin A after treatment with mission siRNA. Expression of scavenger receptor markers CD36 and LOX-1 were also reduced after siRNA transfection 
of cyclophilin A. Protein densities of immunoreactive bands measured by the Quantity One 1D analysis software program. Data are presented as 
mean ± SD (n = 3) and asterisk represents p < 0.05. e ELISA analysis of conditioned medium after treatment with siRNA and chemical inhibitor of 
cyclophilin A, TMN 355. Levels of TNF-α (pg/mL), MCP 1 (pg/mL) and cyclophilin A (ng/mL)
(See figure on next page.) 
Fig. 5 a Effect of TMN355 on cell viability was measured using MTT assay in a time and dose dependent manner. TMN 355 concentrations of 0.5, 
1, 2.5, 5 and 10 μM were tested at 3, 6 and 9 h. b Effect of TMN 355 on protein level expression of cyclophilin A. Protein densities of immunoreac-
tive bands measured by the Quantity One 1D analysis software program. Data are presented as mean ± SD (n = 3) and asterisk represents p < 0.05. 
c mRNA level of cyclophilin A in the presence and absence of TMN 355 after treatment with oxidized LDL. d Confocal microscopy images of Dil 
OXLDL uptake in THP differentiated macrophages after treatment with TMN 355 for 6 h. Mean intensity was quantified using microscope imaging 
software NIS-Elements Viewer, *p < 0.05 was considered significant
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decreases the metabolism of glucose through glycolysis, 
and increases the flux via the alternate pathways which 
activate damaging mechanisms such as PKC pathway, 
hexosamine and polyol pathways and AGE formation. 
These mechanisms eventually increase oxidative stress 
and vascular permeability [19].
Initiation and progression of early atherosclerosis 
lesions are different from the mechanism that causes 
thrombotic plaques [19, 21, 22]. Early atherogenesis 
involves the activation of endothelial cells; recruitment 
of monocytes; cholesterol loading of cells to form foam 
cells; and migration of smooth muscle cells to the intima. 
Fig. 6 Monocyte to macrophage differentiation and lipid uptake in human monocytes isolated from blood. a Representative images of western 
blot analysis of protein level expression of cyclophilin A, CD 36 and LOX 1 in glucose activated human monocytes during foam cell formation. 
Protein densities of immunoreactive bands measured by the Quantity One 1D analysis software program. Data are presented as mean ± SD (n = 3) 
and asterisk represents p < 0.05. b Confocal images of Dil-oxLDL uptake in human monocyte cells differentiated to macrophages. Macrophages 
were incubated with DiI-ox LDL and acetylated LDL (10 μg/mL for 4 h) before and after treatment with cyclophilin A inhibitor or siRNA and exam-
ined using a 559 nm filter. Dil-oxLDL uptake is shown in red and counterstained with Dapi (blue). Mean intensity was quantified using microscope 
imaging software NIS-Elements Viewer, *p < 0.05 was considered significant
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In contrast, advanced plaque progression is influenced 
by processes that promote necrosis and thinning of the 
fibrous cap over the lesion [23]. Monocyte-derived mac-
rophages play important roles in all phases of atheroscle-
rosis [24]. In early lesions, monocytes are recruited to 
the intima by activated endothelium. In the intima they 
become cholesterol-loaded foam cells and participate in 
proatherogenic processes such as inflammation, secre-
tion of proteases and procoagulant/thrombotic factors, 
and formation of the necrotic core of clinically dangerous 
lesions.
When macrophages are exposed to high glucose con-
centrations invitro, inflammation is induced as evident 
from experiments in diabetic mice and subjects [25, 26]. 
A way to reduce inflammation is by blocking cytokine 
action. Inflammatory intermediaries, such as TNF-α, 
interleukins, leptin, MCP-1, C-reactive protein (CRP), 
fibrinogen, angiotensin, retinol binding protein-4, and 
adiponectin are involved in the action of insulin and 
maintenance of inflammatory response [27, 28]. These 
cytokines are involved in insulin resistance and devel-
opment of atherosclerosis. TNF-α, ROS and free fatty 
acids activate inflammatory pathways and modulate the 
expression of numerous genes involved in insulin resist-
ance [29, 30]. Enhanced monocyte activation in diabetes 
induces activation of various cytokines and chemokines 
as well as secretion of monocyte proteins, relevant to the 
pathogenesis of atherosclerosis. One such secreted pro-
tein is cyclophilin A [2] which is found both in extracel-
lular and intracellular forms. Earlier studies have shown 
Fig. 7 a Flow cytometric analysis of Cell Rox (5 µM) uptake by THP differentiated macrophages cultured in high glucose (20 mM/L) during foam cell 
formation. Monocyte differentiated macrophages were treated with cell ROX reagent at a final concentration of 5 µM. Cells treated with cyclophilin 
A had increased oxidized LDL induced cytosolic ROS production. The right panel shows fluorescence intensity analyzed by FACS using FACS Diva 
v8.0 software. Cells were quantitated by subtracting the cell autofluorescence of the treated samples and expressed as mean fluorescence intensity. 
b Thiobarbituric acid-reactive substances (TBARS) assay to assess the levels of lipid peroxides in medium of cultured THP1 cells treated with or 
without cyclophilin A. c Catalase enzyme activity assay of cells treated with oxLDL in the presence and absence of cyclophilin A. Data are presented 
as mean ± SD (n = 3) and asterisk represents p < 0.05
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a strong association between secreted extracellular 
cyclophilin A and vascular disease [8, 10]. The increased 
expression of intracellular cyclophilin A has been 
reported in several stages of atherosclerosis. Deficiency 
of cyclophilin A has been associated with decreased 
low density lipoprotein uptake, vascular cell adhe-
sion molecule 1  (VCAM 1) expression and apoptosis in 
Apolipoprotein deficient mice. Cyclophilin A decreases 
endothelial nitric oxide expression though Kruppel like 
factor 2 transcription repression in endothelial cells [31]. 
Cyclophilin A has been suggested as a secreted oxidative 
stress induced factor from vascular smooth muscle cells 
[32, 33]. Secreted cyclophilin A stimulates extracellular 
signal regulated kinase ½ (ERK ½) and JAK/STAT path-
way invitro [5, 34].
In our experiments with THP-1 cells cultured in high 
glucose conditions (20  mM/L, equivalent to 360  mg/
dL of blood sugar levels in humans), we observed an 
increased adhesion of monocytes to the transwell inserts 
in the presence of cyclophilin A. Extracellular cyclophi-
lin A is reported to trigger the activation of endothelial 
cells to produce various adhesion molecules to attract 
monocytes [35–37]. These adhesion molecules along 
with other proinflammatory cytokines and extracellular 
cyclophilin A induce the adhesion of monocytes to the 
vascular endothelium. As monocyte pass through the 
endothelial layer and differentiate, they produce vari-
ous bioactive factors such as TNF-α, interleukins, MCP 
1 etc., which promote inflammation in atherosclerosis. 
Cyclophilin A is associated with this activation process 
of monocytes [38–40]. We discovered that migration 
elicited in the presence of cyclophilin A was equal to 
that elicited when lipopolysaccharides (LPS) was used 
to induce cell migration suggesting that cyclophilin A 
exhibits similar chemokine activity as MCP-1 and TNF-α 
in high glucose conditions. Cyclophilin A induces accu-
mulation of other leukocytes, such as neutrophils, eosin-
ophils, T lymphocytes within atheroma lesions, which 
facilitate their adhesion to the injured endothelium [41, 
42]. Cyclophilin A induces a rapid inflammatory response 
characterized by neutrophil influx, when injected in vivo 
[43]. Activated T lymphocytes and monocytes, which are 
critical for the development of atherosclerosis, show high 
chemotaxis to extracellular cyclophilin A and its receptor 
CD147 [37]. Although the exact mechanism is unclear, 
cyclophilin A is implicated in chemokine receptor C-X-C 
chemokine receptor (CXCR) 4-mediated chemotaxis by 
regulating mitogen-activated protein kinase (MAPK) 
[44]. Cyclophilin A strongly upregulated stromal cell 
derived factor-1α (SDF-1) and its specific receptor 
CXCR4 gene expression in C57B1/6J mice and promot-
ing neovascularisation in ischemic limb injury by increas-
ing the recruitment of inflammatory cells into ischemic 
limbs [45]. Taken together these results implicate cyclo-
philin A as a major chemokine on par with other inflam-
matory cytokines modulating atherogenesis in diabetes.
The next step after adhesion is migration of monocytes 
into the sub endothelial space where they differentiate 
into macrophages. This step can be reproduced in the 
cell culture using EaHy.926 as an endothelial mono layer 
and THP-1 cells as migratory cells. Cyclophilin A added 
in the lower chamber markedly increased transmigra-
tion of monocytes and differentiation into macrophages. 
High glucose per se enhances transendothelial migration 
of monocytes, possibly by disruption of endothelial adhe-
rens junctions and promoting movement of monocytes 
through the protein kinase C mediated tyrosine phos-
phorylation of vascular endothelial cadherin [46, 47]. 
It is possible that extracellular cyclophilin A expressed 
by high glucose activated monocytes stimulates the 
endothelial cells to facilitate the transendothelial migra-
tion of monocytes by inducing the expression of adhe-
sion molecules via MAPK signalling pathway [35, 48]. 
The differentiation of monocyte to macrophages is asso-
ciated with increased expression of scavenger receptors, 
LOX-1 and CD 36 [49]. In our study, treatment of THP-1 
cells and human monocytes with cyclophilin A resulted 
in increased expression of CD36 and LOX-1. Subse-
quently when cyclophilin A was inhibited with siRNA 
and TMN355, the expression of these scavenger recep-
tors was reduced. The expression of CD36 and LOX-1 
are dependent on oxidative stress induced by vascular 
injury and hyperglycaemia. Further, cyclophilin A being 
a molecular chaperone may be required for folding and/
or transporting LOX-1 and CD 36 to the cell membrane. 
This could be the reason for reduced the expression of 
scavenger proteins in the absence of cyclophilin A [50]. 
Cyclophilin A is also reported as a pro apoptotic cytokine 
which triggers apoptosis of endothelial cells [38]. Cyclo-
philin A deficiency is associated with a marked decrease 
in apoptosis of endothelial cells. Studies using mac-
rophages from patients with type 2 diabetes mellitus and 
diabetic mice reveal that macrophages in diabetic con-
ditions have an increased activation of pro atherogenic 
pathways [51, 52]. Mice models which lacks CD 36 have 
reduced oxLDL internalisation and are less prone to foam 
cell formation in vitro [53, 54].
Foam cell formation on treatment with OxLDL is 
well documented [55]. We focussed on the influence of 
cyclophilin A in OxLDL uptake by monocyte derived 
macrophages. Cyclophilin A increased the lipid uptake 
as evident from our qualitative and quantitative assays 
(p  <  0.05). Inhibition of cyclophilin A by silencing or 
chemical inhibitors strongly reversed this process by 
reducing lipid uptake. Possibly siRNA mediated knock-
down may have removed the target mRNA of cyclophilin 
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A and consequently the protein from the macrophages 
resulting in decreased lipid uptake. The chemical inhibi-
tion by TMN 355 may have blocked the function of the 
protein thus resulting in a similar effect. These results 
suggest the importance of cyclophilin A in the process of 
foam cell formation in macrophages. There are reports 
that apolipoprotein E deficient mice (apoE) fed with high-
cholesterol diet develop severe atherosclerosis compared 
to apoE and cyclophilin A-deficient mice, indicating that 
cyclophilin A deficiency in  vivo decreases atheroscle-
rotic lesions [56]. We observed that silencing of cyclo-
philin A also decreased lipid uptake by macrophages in 
high glucose conditions. Interestingly, the extracellular 
cyclophilin A during this process mirrored the intracellu-
lar cyclophilin A expression. This is in agreement to our 
earlier report on cyclophilin A expression in circulating 
monocytes [3] in patients with type 2 diabetes mellitus.
Macrophages have increased expression of inherent 
cyclophilin A probably because of more redox activity 
in the sub endothelial space [57, 58]. At the same time, 
the levels of extracellular cyclophilin A were also higher 
as evident from immunoassays. Studies on lipid uptake in 
atherosclerosis models have reported increased expres-
sions of matrix metalloproteinase 9 (MMP9) in cyclo-
philin A mediated foam cell formation. MMP-9 secretion 
was reported significantly reduced when treated with 
the cyclophilin A inhibitor NIM811 [59]. Several experi-
ments have demonstrated that the expression of mac-
rophage colony stimulating factor (M-CSF) and MMPs 
are effectively retarded after inhibition of cyclophilin A. 
The M-CSF plays an important role in differentiation 
of monocytes to lipid laden macrophages by increas-
ing expression of scavenger receptors. These function 
by internalising modified lipoproteins to form the initial 
lesion [35, 48]. A reported ligand of cyclophilin A, extra-
cellular matrix metalloproteinase inducer (EMMPRIN) 
has been found in atherosclerotic plaques of ApoE defi-
cient mice which suggest that cyclophilin A may play a 
role both in initiation of lesion as well as vulnerability of 
the plaque for rupture [59].
Fig. 8 a Oxidative modification of lipoprotein in the presence of high glucose in the vascular system activates monocytes as well as the endothe-
lial cells facilitating adhesion of circulating monocytes. Activated endothelial cells secrete chemokines and promote monocyte rolling, tether-
ing and then transmigration into the subendothelial space. b These monocyte then firmly adhere to the endothelial cells and differentiate into 
macrophages. Macrophages engulf oxidised lipoproteins to form foam cells. These modifications incite an inflammatory response and result in 
an increase in the levels of cytokines such as MCP-1, TNF-α and extracellular cyclophilin A. c When monocyte derived macrophages are treated 
with either siRNA or chemical inhibitor TMN 355, to silence/inhibit cyclophilin A it leads to a decrease in expression of CD36 and LOX-1 indicating 
reduced monocyte-macrophage differentiation as well as reduced lipid uptake. The levels of inflammatory cytokines, MCP-1, TNF-α and cyclophilin 
A also decreases. This highlights the role of cyclophilin A in promoting vascular inflammation in hyperglycemia
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Macrophages in an attempt to eliminate excessive lipids 
proliferate and form more foam cells. Cyclophilin A is 
crucial for macrophage proliferation which is dependent 
on macrophage M- CSF. This proliferation is dependent 
on regulation by cyclophilin A [48]. As a consequence of 
increase in extracellular and intracellular cyclophilin A 
an increasing number of foam cells accumulate eventu-
ally forming a vascular lesion. This entire process is insti-
gated by redox activity. Cyclophilin A has been suggested 
as an oxidative stress induced factor which mediates the 
production of ROS in circulation as well as in the intima 
[31, 58]. Our findings in this study support this view. The 
oxidative stress levels were increased in macrophages 
treated with cyclophilin A. Formation of ROS and lipid 
peroxidation activity may be stimulated by hypergly-
cemia as well as the presence of increased intracellular 
and extracellular cyclophilin A. Other factors that could 
induce ROS are hypoxia, secreted factors such as tyros-
ine kinase receptors etc. [60]. Intracellular ROS also 
increases expression and secretion of cyclophilin A in 
vascular smooth muscle cells (VSMCs) [56]. Our results 
suggests that increased ROS levels due to intracellular 
cyclophilin A activity can be detected as early as foam 
cell formation of monocytes which is the primary step for 
plaque initiation in the arterial wall. A limitation of our 
study is the in vitro nature of our experiments, however 
we have shown increased lipid uptake in the presence of 
cyclophilin A by human monocytes isolated from periph-
eral blood mononuclear cells. We have also demonstrated 
that silencing of cyclophilin A in human monocytes can 
attenuate lipid uptake to a large extent.
Thus, cyclophilin A in both extracellular and intracel-
lular forms promotes atherogenesis in hyperglycaemic 
conditions. Our results implicate cyclophilin A at vari-
ous stages of atherogenesis such as monocyte adhesion, 
transmigration, monocyte to macrophage differentiation 
and foam cell formation (Fig.  8). Possibly, high glucose 
levels in circulation increases redox activity and facili-
tates adhesion of circulating monocytes to the endothe-
lium and its subsequent differentiation into macrophages 
in the sub endothelial space. The presence of extracellular 
cyclophilin A secreted from glucose activated monocytes 
in circulation further enhances this adhesion and trans-
migration process. Increased intracellular cyclophilin A 
within macrophages increases scavenger receptors such 
as CD 36 on its surface owing to the chaperone activity of 
cyclophilin A. This accelerates accumulation of modified 
lipoproteins in macrophages subsequently forming foam 
cells. This may trigger an inflammatory response increas-
ing cytokine levels leading to secretion of the intracellu-
lar cyclophilin A into the circulation in its extracellular 
form. However the exact mechanism of this secretory 
process requires further contemplation.
In our attempt to understand the mechanism underly-
ing the process of cyclophilin A induced foam cell forma-
tion by monocytes activated by high glucose we found 
that cyclophilin A upregulates scavenger receptors and 
increases redox activity as well as levels of proinflam-
matory cytokines leading to increase in lipid uptake 
by macrophages. This is the first study which evaluates 
cyclophilin A as a regulatory protein in vascular lesion 
formation in high glucose conditions.
To summarize, we describe here three mechanisms by 
which cyclophilin A promotes atherogenesis in diabe-
tes mellitus. First, cyclophilin A acts as a chemokine and 
increases adhesion and transmigration of glucose acti-
vated monocytes into the sub endothelial space. Second, 
cyclophilin A modulates monocyte to macrophage differ-
entiation by regulating the expression of scavenger recep-
tors. Third, inhibition of cyclophilin A reduces oxLDL 
uptake which is mediated through oxidative stress. All 
these mechanisms together contribute to vascular inflam-
mation in hyperglycemia. In conclusion, our results dem-
onstrate that high concentrations of glucose results in 
increased monocyte adhesion, transmigration, differentia-
tion and formation of foam cells through a cyclophilin A 
mediated inflammatory process. It is possible that target-
ing cyclophilin A activity using inhibitory agents or mol-
ecules may retard progression of atherosclerotic lesions in 
diabetes. In this context, cyclophilin A gains clinical sig-
nificance as a target for treatment strategy in preventing 
vascular complications in patients with diabetes.
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